A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination with Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

开始日期2025-12-31

申办/合作机构

University of Maryland Baltimore

[+1]

NCT06769126

/ Not yet recruiting临床2期IIT

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.

开始日期2025-09-08

申办/合作机构

SWOG

[+1]

NCT06820957

/ Not yet recruiting临床2/3期IIT

Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination With Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This phase II/III trial compares the effect of vincristine, irinotecan, and regorafenib (VIrR) in combination with vincristine, doxorubicin, cyclophosphamide (VDC), ifosfamide and etoposide (IE) to usual treatment with VDC/IE for the treatment of newly diagnosed Ewing sarcoma or other round cell sarcomas that have spread from where they first started (primary site) to other places in the body (metastatic). Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Regorafenib, a type of kinase inhibitor and a type of antiangiogenesis agent, blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells. It may also lower the body's immune response. Ifosfamide, a type of alkylating agent and a type of antimetabolite, attaches to DNA in cells and may kill tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Giving VIrR/VDC/IE may be more effective than usual treatment with VDC/IE in treating patients with newly diagnosed metastatic Ewing sarcoma or other round cell sarcomas.

开始日期2025-07-15

申办/合作机构

The Children's Oncology Group Foundation, Inc.

100 项与依托泊苷相关的临床结果

登录后查看更多信息

100 项与依托泊苷相关的转化医学

登录后查看更多信息

100 项与依托泊苷相关的专利（医药）

登录后查看更多信息

35,399

项与依托泊苷相关的文献（医药）

2025-12-31·NMC case report journal

A Primary Spinal Intramedullary Mixed Germ Cell Tumor: A Case Report and Literature Review

Article

作者: SHIMAUCHI-OHTAKI, Hiroya ; HORIGUCHI, Keishi ; HIRATO, Junko ; NAKATA, Satoshi ; HONDA, Fumiaki ; YOKOO, Hideaki ; OYA, Soichi ; GOTO, Yuta ; TOMOMASA, Ran ; NAKAMURA, Shunsuke

Central nervous system germ cell tumors are rare and account for 2% to 3% of all central nervous system tumors in Japan. Here, we report an extremely rare case of a primary spinal intramedullary mixed germ cell tumor. A 33-year-old man presented with a chief report of dysuria and numbness in the right lower extremity. Magnetic resonance imaging revealed a mass lesion on the left side of the intramedullary spinal cord at the Th10-11 vertebral body level with hyperintensity on T2-weighted images, isointensity on T1-weighted images, and uniform contrast in gadolinium. Cerebrospinal fluid examination revealed a few atypical cells. Although tumor removal using the posterior median sulcus approach was attempted, only a biopsy was performed because intraoperative rapid pathology suggested a possible diagnosis of germinoma. Permanent pathology revealed a mixed germ cell tumor (mainly comprising a germinoma with a yolk sac tumor). Postoperatively, cerebrospinal irradiation and 8 courses of the carboplatin and etoposide regimen were administered. No recurrence or new lesions were observed on magnetic resonance imaging at 94 months postoperatively. Our extensive literature search found only 4 cases of a mixed germ cell tumor of primary intramedullary origin in the spinal cord. Most spinal germ cell tumors described in the literature are either germinomas or mature teratomas; however, mixed germ cell tumors can also occur, albeit infrequently. Although additional cases need to be accumulated, our case suggests that yolk sac elements in spinal mixed germ cell tumors might not be directly associated with poor life expectancy.

2025-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Synthesis, in vitro and in silico studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity via G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II

Article

作者: Break, Mohammed Khaled Bin ; Alkahtani, Hamad M. ; Ansari, Siddique Akber ; Alshammari, Maali D. ; Katamesh, Ahmed A. ; Albadari, Najah

A novel chrysin-ferrocene Schiff base (CFSB) was synthesised as a potential anticancer agent. CFSB demonstrated high cytotoxicity against cancer cells with HepG2 (liver) being the most susceptible (IC₅₀ = 3.11 µM). The compound was less toxic towards normal MRC5 cells and exhibited ∼5-fold selectivity towards most cancer cells. CFSB caused G1-phase arrest, induced caspase-dependent apoptosis by increasing Bax/Bcl2 ratio and reduced metastasis by decreasing MMP9 in HepG2. Furthermore, CFSB was inactive against CDK2, EGFR, TrkA and VEGFR, but it strongly inhibited topoisomerase II (IC₅₀ = 20 µM) with potency comparable to etoposide (IC₅₀ = 15 µM), while weak inhibition was observed against tubulin (IC₅₀ = 76 µM). DFT calculations revealed that CFSB had desirable reactivity, while docking indicated high binding affinity with topoisomerase II. Molecular dynamics and MM-GBSA analyses showed that CFSB-topoisomerase II complex was stable with favourable binding energies, while in silico ADMET studies showed drug-like properties for CFSB.

2025-12-31·ANNALS OF MEDICINE

Construction of a novel prognostic model based on lncRNAs-related to DNA damage repair for predicting the prognosis of clear cell renal cell carcinoma

Article

作者: Chen, Peng ; Li, Jian ; Tian, Renli

BACKGROUND:

CcRCC has the characteristics of high aggression, high metastasis, high mortality, wide tumour heterogeneity and variable clinical course. The purpose of this study was to explore the potential value of lncRNAs-related to DNA damage repair (DDR) in predicting the prognosis of ccRCC by construction and verification a novel prognostic model.

METHODS:

RNA-seq data and clinical data of ccRCC were downloaded from public databases. Subsequently, Pearson correlation analysis and differential expression analysis were performed to identify DElncRNAs-related to DDR. Then, through univariate Cox analysis and LASSO analysis, the DElncRNAs-related to DDR associated with prognosis were screened for the construction of novel risk score prognostic model. In addition, functional annotation, tumour mutation burden, immune correlation and drug sensitivity analyses were performed based on risk score to assess the characteristics of patients in different risk score groups.

RESULTS:

Based on univariate Cox analysis and LASSO analysis, four best DElncRNAs-related to DDR were selected. Subsequently, a novel risk score prognostic model based on these four DElncRNAs was constructed through LASSO. Multivariate Cox analysis showed that risk score and age were independent prognostic factors for ccRCC (p < 0.05). Functional enrichment analysis showed that DDR-related biological processes were mainly enriched in the high risk group. The highly mutated genes in the high and low risk groups were the same (VHL, PBRM1 and TTN), but they also had their own unique mutated genes. Pearson correlation analysis showed that the risk score was significantly (p < 0.05) positively correlated with the infiltration degree of CD8 T cells evaluated by six algorithms. In addition, it was found that the high and low risk groups had different sensitivities to the drugs Etoposide, Imatinib, Sorafenib, Bosutinib and Sunitinib.

CONCLUSION:

A novel prognostic model was constructed based on four DElncRNAs-related to DDR. The model has satisfactory accuracy in predicting survival of ccRCC patients.

742

项与依托泊苷相关的新闻（医药）

2025-05-30

·医脉通

国际视野赋能肺移植诊疗革新——“海外移植专家中国行”系列学术活动在京成功举办

导读肺移植是众多终末期肺疾病的终极治疗手段。随着肺移植技术的日臻成熟及术后管理的逐渐完善，肺移植手术成功率与术后受者生存率大幅提升。然而，慢性移植肺功能障碍（CLAD）作为肺移植术后远期的主要并发症，严重影响受者术后的长期生存，成为肺移植基础和临床研究领域重要的课题之一。在此背景下，北京中康联公益基金会发起了“海外移植专家中国行项目”，旨在搭建高水平的中外学术交流平台，为我国肺移植事业的规范化发展注入新动能！2025年5月20日-21日，“海外移植专家中国行项目”特邀德国汉诺威医学院Jens Gottlieb教授来华，与国内肺移植领域专家共聚一堂，通过主题报告、案例分享与多学科讨论等形式，深入探讨肺移植全程化管理与并发症防治的前沿策略，助力我国肺移植技术与国际接轨并实现创新发展。医脉通特此整理会议精彩内容，以飨读者。Part 01以多学科协作为桥梁，共探CLAD诊疗前沿开场致辞2025年5月20日，在中日友好医院代华平教授、陈文慧教授的共同主持下，首场中外交流活动逐渐拉开帷幕。专家们表示很荣幸能够邀请到在肺移植全程管理及CLAD领域具有深厚造诣的国际专家Jens Gottlieb教授，与国内血液科、药学部和病理科的同道们进行跨学科、跨地域的深入交流。代华平教授致辞陈文慧教授致辞学术交流一、CLAD诊疗新进展：从流行病学特征到未来治疗策略的深度解析Jens Gottlieb教授以《CLAD诊疗进展》为题，系统梳理了CLAD的流行病学、表型分类、治疗策略与相关研究进展及未来研究方法。CLAD的全球患病率约为9例/百万人口，肺移植受者中CLAD累计发病率较高，术后5年发生率约30%~60%，且按照肺功能特征和影像学诊断分为不同表型分型（如闭塞性细支气管炎综合征[BOS]、限制性同种异体移植综合征[RAS]）。CLAD的风险因素较多，包括免疫相关因素（急性排斥反应、免疫抑制不足）、感染与炎症因素（持续性感染、病毒感染）、非免疫因素（非感染性损伤、空气暴露、供体因素）等。CLAD对生存和生活质量影响严重，患者5年生存率仅26%~30%，同时导致肺功能下降、活动能力恶化等。然而，目前仍缺乏能够完全阻止或逆转CLAD进展的根治性药物，现有治疗仅能在一定程度上延缓部分患者病情的进展。未来，亟需通过多学科协作、研发生物标志物以及探索新型靶向药物来突破治疗瓶颈。同时，积极优化供肺评估与免疫抑制策略，以实现从治疗并发症向预防损伤的范式转变。王诗尧大夫主持Jens Gottlieb教授作主题报告二、肺移植后淋巴瘤伴BOS：复杂病例的多学科协作中日友好医院王诗尧大夫和彭凯悦大夫从临床治疗和病理学角度分享了一例肺移植后EB病毒阴性移植后淋巴组织增殖性疾病（PTLD）。患者在术后11个月确诊为弥漫大B细胞淋巴瘤（DLBCL）合并噬血细胞综合征（HLH），利妥昔单抗+依托泊苷治疗后达到完全缓解。患者在术后3年出现进行性呼吸困难，冷冻肺活检（TBCB）病理检查证实为闭塞性细支气管炎（BO），给予糖皮质激素冲击等对症治疗。该病例展示了基于对肺移植后并发症的全面认知，快速识别并确诊了EBV阴性的PTLD。此外，PTLD患者因免疫抑制调整更易发生CLAD，因此需加强肺功能监测。与会专家在讨论中也进一步强调了多学科协作在这一复杂病例中的关键作用。通过这种多学科的合作模式，能够助力精准诊断和治疗方案的优化，未来也需进一步探索预防性免疫调控或新型靶向治疗，以提升这部分患者的预后。王诗尧大夫作病例报告彭凯悦大夫作病理解读三、案例解析：滤泡淋巴瘤相关BOS的肺移植探索随后，中日友好医院徐九洋大夫分享了一例滤泡淋巴瘤并发BO的肺移植手术案例。患者滤泡淋巴瘤并发副肿瘤性天疱疮（PNP)、BO，化疗3周期后淋巴瘤评估部分缓解，但BO导致II型呼吸衰竭进行性加重，气切机械通气3月余，经多学科评估后接受双侧序贯肺移植。术后，通过优化免疫抑制方案，实现抗肿瘤治疗、移植肺免疫抑制及感染之间的平衡。依靠多学科协作制定的精准治疗方案，患者术后1月出院并恢复正常生活，术后6个月复查时肺功能大幅改善，PET-CT显示淋巴瘤仍稳定于部分缓解状态。该病例强调了肺移植在挽救终末期患者中的价值，同时也展示了肺移植后肿瘤管理与并发症处理的复杂性。最后，徐九洋大夫强调，早期的病理干预及多学科协作在改善患者预后方面起着关键作用，未来在肺移植领域的发展中仍需持续优化。徐九洋大夫作病例报告四、造血干细胞移植后肺部cGvHD管理：从病理机制到临床实践北京大学人民医院卢冰冰教授分享了造血干细胞移植后肺部慢性移植物抗宿主病（cGVHD）的管理经验，并详细解析肺部cGVHD的病理分期与治疗策略。卢教授指出，肺部cGVHD可分为炎症期（淋巴细胞性细支气管炎[LB]）、免疫失调期及纤维化期（BO）等阶段，在LB阶段，治疗目标是改善或稳定肺功能，而在BO阶段，则应关注如何延缓肺功能的进一步下降从而达到改善。在治疗策略方面，卢教授建议结合国际指南，并整合新兴疗法，如ROCK2抑制剂、体外光分离置换疗法（ECP）等。同时，在治疗过程中需谨慎权衡白血病复发的风险与免疫抑制的平衡。最后，卢教授强调了BOS早期识别与分层治疗的重要性，并指出结合多学科诊疗模式有助于优化造血干细胞移植后复杂并发症的管理，从而提高患者的预后和生活质量。卢冰冰教授作主题报告讨论互动在专题讨论环节，Jens Gottlieb教授、陈文慧教授及以上专题分享的教授与北京大学第一医院尹玥教授、北京协和医院王为教授、中日友好医院李振玲教授、刑斌大夫、郭超大夫、彭凯悦大夫、王晓星药师等专家围绕肺移植后CLAD和造血干细胞移植后肺部GVHD等相关话题展开深入探讨。与会专家强调，肺移植需严格把握时机与适应证，建议在原发疾病稳定且无严重合并症的情况下，尽早将患者转诊至经验丰富的移植中心，并通过多学科协作制定个体化的治疗方案，以最大化生存获益。此外，BOS的发病机制涉及体液免疫与细胞免疫的相互作用，而主要组织相容性复合体（MHC）的兼容性同样会影响移植的预后。因此，专家们一致认为，未来亟需通过跨学科研究深入解析相关的分子机制，并开发靶向的新型疗法，以改善复杂患者的生存结局。对于部分惰性淋巴瘤患者，并发BO和/或PNP，当BO所致呼吸衰竭成为最主要的致命病因时，肺移植在经过多学科严格评估后可能带来生存获益。值得注意的是，移植前应避免使用高强度化疗（如含烷化剂的方案），优先选择靶向治疗。且对于合并BO的患者，平衡抗肿瘤治疗与免疫抑制的关系同样具有重要的临床意义。此次讨论聚焦肺移植术后的CLAD和血液移植后肺部cGVHD的异同，邀请肺移植管理专家和血液科等多学科专家共同进行深入的学术交流。专家们一致认为，肺移植为那些在血液移植后因肺部cGVHD而面临治疗困境的患者提供了生存的希望。这种探讨和学术交流模式可以有效提升CLAD和肺部cGVHD患者的生存率，从而推动临床医学的发展。Part 02同享肺移植管理经验，开启临床实践创新新征程5月21日上午8:30，中日友好医院曹彬教授、梁朝阳教授和陈文慧教授邀请Jens Gottlieb教授来到中日友好医院，与带领的肺移植管理内外科团队进行学术交流。曹彬教授表示，前期的交流已让与会者接触到国际前沿理念，今日的交流将聚焦临床经验分享，旨在通过交流探讨，共同梳理当前领域发展的瓶颈，并明确未来研究与实践的方向，从而进一步优化我国肺移植全程管理的路径，推动相关领域的发展迈向更高水平。曹彬教授致辞陈文慧教授致辞学术交流一、肺移植临床现状：本土数据与国际对标梁朝阳教授系统介绍了中日友好医院肺移植中心的发展现状。中日友好医院于2017年正式成立肺移植中心，并迅速进入快速发展阶段。目前，中心年手术量稳定在80-100例，涵盖双肺移植、肺再移植等复杂病例。在科研方面，中日友好医院建立了供肺获取与修复体系，积极探索体外肺灌注（EVLP）和新型保存液等技术，以提升边缘供肺的利用率。同时，通过多中心研究优化免疫抑制方案，降低CLAD等并发症的发生率，现已成为国内领先的肺移植诊疗与研究中心。未来，需要优化全国供体分配系统，促进优质资源下沉，推广居家肺功能监测等早期预警手段，并加强国际合作，借鉴欧美在供体维护和免疫管理方面的先进经验，以进一步推动肺移植事业的发展。梁朝阳教授作主题报告二、汉诺威医学院管理经验分享：肺移植供受者管理困境与创新随后，Jens Gottlieb教授分享了其所在中心的肺移植管理临床经验。汉诺威医学院的肺移植始于1987年，至今已有超过35年的历史。由于德国禁止使用心脏死亡后捐赠（DCD）供体以及跨境捐赠的限制，导致供体率较低，同时边缘供体的使用率较高。此外，CLAD仍是肺移植患者的主要死因。在随访管理中，汉诺威中心采用“一站式”随访模式，由呼吸科主导，整合肺功能检测、支气管镜、影像及血药浓度监测。此外，约五分之三的患者使用远程肺功能设备，实现居家肺功能的远程管理，以期降低CLAD发生率。最后，Jens Gottlieb教授强调了数字化工具在早期预警中的关键作用，并提到，中国未来可大力发展远程医疗，通过AI算法整合多中心数据，提前识别CLAD高危患者，从而实现科技赋能医疗，提升患者的管理与预后。Jens Gottlieb教授作主题报告医院参访陈文慧教授带领Gottlieb教授参观了医院呼吸中心诊察部呼吸介入平台，中日友好医院侯刚教授详细介绍了科室配备的国内外先进诊疗设备，同时分享了科室在肺移植术后介入诊疗领域的创新理念。此次交流通过中外专家的深度对话，彰显了中国在肺移植临床研究与规范化管理领域的快速进步，为推动全球肺移植技术协同发展提供了“中国范式”。参观交流现场总结正如曹彬教授与陈文慧教授总结道，本次为期两天的学术活动，不仅是中外经验的交汇，更是临床实践与科研创新的催化剂。通过与Gottlieb教授互通肺移植管理体系和CLAD诊疗理念，我国肺移植领域可以在技术升级的有利优势下，进一步优化规范化随访和并发症管理。期待通过持续的国际合作，使中国肺移植专家有更多的机会参与全球化医学平台的交流和互动，使得中国肺移植患者诊疗更好地与国际先进理念与技术接轨，让每一例移植手术都成为生命的新起点。展望未来，随着“海外移植专家中国行”项目的持续推进，我国肺移植领域有望在CLAD等复杂并发症的防治中实现突破，结合国际先进的理念和自身优势，形成具有中国特色的肺移植诊疗体系，为全球器官移植医学的发展贡献中国力量。免责声明：该信息仅作医学和科研参考，赛诺菲不建议以任何与您所在国家所批准的处方信息不符的方式使用本产品。本材料仅供医疗卫生专业人士使用。4M编号：MAT-CN-2510195-1.0审核时间：05/2025撰写：Isa审校：Vera排版：Atai执行：Atai本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

2025-05-30

·GlobeNewswire-Health Care

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). "The breadth of new MRD evidence being shared across various blood cancer types at ASCO and EHA this year highlights the transformative impact MRD is having on clinical care and drug development," said Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies. "These data presentations are a testament to the central role that clonoSEQ MRD testing now plays in clinical management and drug development across lymphoid cancers, particularly when combined with several clonoSEQ data presentations in diffuse large B-cell lymphoma (DLBCL) anticipated at the 18th International Conference on Malignant Lymphoma (iCML) on June 17-21, 2025 in Lugano, Switzerland." Selected presentations include: Data advancing the clinical actionability of clonoSEQ MRD testing Results from MIDAS, a phase 3 randomized study of 718 transplant-eligible, newly diagnosed multiple myeloma (NDMM) patients, demonstrate the use of MRD status to guide therapy post-induction. (ASCO Abstract 7500, June 3, 9:45-9:57 a.m. CDT, S100bc, McCormick Place Convention Center)Interim data from ADVANCE, a phase 2 randomized study of 306 transplant-eligible patients with NDMM shows the impact of MRD-guided assessments post-induction (ASCO Abstract 7503, June 3, 10:21-10:33 a.m. CDT, S100bc, McCormick Place Convention Center)Interim results from VENETOSTOP, a phase 2 study of 66 CLL patients, report the use of MRD status to shorten duration of venetoclax-based therapy. (EHA Abstract PS1568, June 14, 6:30 p.m. CEST, Poster Hall, Milano Convention Centre) Studies utilizing clonoSEQ MRD assessment as a critical indicator of quadruplet regimen efficacy in multiple myeloma Results from the phase 3 IsKia study of 151 transplant-eligible NDMM patients demonstrates increased rates of sustained MRD negativity at 10-6 with isatuximab plus carfilzomib, lenalidomide, and dexamethasone. (ASCO Abstract 7502, June 3, 10:09-10:21 a.m. CDT, S100bc, McCormick Place Convention Center) Follow-up data from PERSEUS, a phase 3 trial of 709 transplant-eligible patients with NDMM reports the impact of sustained MRD negativity status on progression free survival (PFS) with subcutaneous daratumumab plus bortezomib, lenalidomide and dexamethasone (D-VRd) induction and DR maintenance. (ASCO Abstract 7501, June 3, 9:57-10:09 a.m. CDT, S100bc, McCormick Place Convention Center) Results from DREAMM-8, a Phase 3 study in 302 patients with relapsed or refractory multiple myeloma, found superior PFS and higher MRD negativity rates in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) as compared to standard-of-care pomalidomide, bortezomib, and dexamethasone (PVd). (ASCO Abstract 7515, June 2, 9:00-9:06 a.m. CDT E450b, McCormick Place Convention Center) Data to be presented at ASCO: Presentation Type and NumberTitlePresentation TimingB-Cell Acute Lymphoblastic LeukemiaPoster Presentation6540Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL)Sunday, June 19 a.m.-12 p.m. CDTPoster Presentation6543Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemiaSunday, June 19 a.m.-12 p.m. CDTMultiple MyelomaOral Presentation7500*MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trialTuesday, June 39:45-9:57 a.m. CDTOral Presentation7501Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trialTuesday, June 39:57-10:09 a.m. CDTOral Presentation7502Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)Tuesday, June 310:09-10:21 a.m. CDTOral Presentation7503*Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trialTuesday, June 310:21-10:33 a.m. CDTOral Presentation7507*Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)Tuesday, June 311:57 a.m.-12:09 p.m. CDTOral Presentation7515Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trialMonday, June 29-9:06 a.m. CDTOral Presentation7516Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS studyMonday, June 29:06-9:12 a.m. CDTASCO Oral Presentation7517*Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ studyMonday, June 29:12-9:18 a.m. CDTPoster Presentation7529Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysisSunday, June 19 a.m.-12 p.m. CDTPoster Presentation7535Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM)Sunday, June 19 a.m.-12 p.m. CDTASCO Poster Presentation7551*Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysisSunday, June 19 a.m.-12 p.m. CDT Data to be presented at EHA: Presentation Type and NumberTitlePresentation TimingB-Cell Acute Lymphoblastic LeukemiaOral PresentationS112Safety and efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL): results from a phase 1/2 dose expansion studySunday, June 1511:30-11:45 a.m. CESTOral PresentationS117Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia: early results from the phase 1/2 SYRUS studyFriday, June 135:30-5:45 p.m. CESTPoster PresentationPF372Donor-derived, allogeneic CD19/CD22-CAR T cells with myeloablative graft-engineered Allo-HCT for high-risk B-ALLFriday, June 136:30 p.m. CESTChronic Lymphocytic LeukemiaPoster PresentationPF575Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (ReVenG) in patients with recurrent chronic lymphocytic leukemia (CLL)Friday, June 136:30 p.m. CESTPoster PresentationPS1568Using minimal residual disease status to guide venetoclax treatment duration in patients with chronic lymphocytic leukemia: interim results from the phase II VENETOSTOP studySaturday, June 146:30 p.m. CESTFollicular LymphomaPoster PresentationPF881Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed/refractory follicular lymphomaFriday, June 136:30 p.m. CESTPoster PresentationPS21504-year update of phase 2 ELARA trial: clinical outcomes of tisagenlecleucel in patients (pts) with high-risk relapsed/refractory follicular lymphoma (R/R FL)Saturday, June 146:30 p.m. CESTMantle Cell Lymphoma Poster PresentationPF882Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: results from the phase 3 ECHO trialFriday, June 136:30 p.m. CESTMultiple MyelomaOral PresentationS201Phase 2 registrational study of anitocabtagene autoleucel for relapsed and/or refractory multiple myeloma (RRMM): updated results from IMMAGINE-1Saturday, June 145:15-5:30 p.m. CESTOral PresentationS205*Minimal residual disease-driven strategy following isatuximab-carfilzomib-lenalidomide-dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma: Primary endpoints of the phase 3 MIDAS trialSunday, June 1511:00-11:15 a.m. CESTOral Presentation S207*A randomized, multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) for the treatment of patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trialSunday, June 1511:30-11:45 a.m. CESTOral PresentationS208*Analysis of sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)Sunday, June 1511:45 a.m.-12 p.m. CESTPoster PresentationPF727Isa-vrd improves outcomes in high-risk (HR) newly diagnosed transplant-ineligible multiple myeloma (NDMM TI) using the IMS/IMWG consensus HR definition: results from the BENEFIT phase 3 trial (IFM 2020-05)Friday, June 136:30 p.m. CESTPoster Presentation PF729*Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): outcomes in patients with 1q21+ status in the phase 3 IMROZ studyFriday, June 136:30 p.m. CESTPoster PresentationPF750Isatuximab, bortezomib, lenalidomide, dexamethasone (Isa-VRd) in patients with transplant-ineligible (TI) newly diagnosed myeloma (NDMM) and plasmacytomas: IMROZ subgroup analysisFriday, June 136:30 p.m. CESTPoster PresentationPF754Interim analysis of MRD-guided maintenance therapy with belantamab mafodotin and lenalidomide after Auto-HCT in newly diagnosed multiple myelomaFriday, June 136:30 p.m. CESTPoster Presentation PS1722*Positron emission tomography with computed tomography and minimal residual disease for efficacy assessment in transplant-ineligible newly diagnosed myeloma patients: IMROZ analysisSaturday, June 146:30 p.m. CEST *Indicates data to be presented at both ASCO and EHA. About clonoSEQ clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL. clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary. About Adaptive Biotechnologies Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. Forward Looking Statements This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations and FP&A 201-396-1687 investors@adaptivebiotech.com ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@adaptivebiotech.com

临床2期临床3期临床结果ASCO会议

2025-05-29

·CPHI制药在线

ASCO 2025：中国药企从“跟跑”到“引领”

关注并星标CPHI制药在线肿瘤领域权威学术交流会ASCO 2025，即将于5月30日-6月3日在美国芝加哥举行。根据官网已公布的摘要信息，今年ASCO，中国药企有超70项研究入选口头报告（Oral Abstracts），其中不乏FIC、BIC。我们选取其中5家中国药企，来领略一下中国军团的创新力量。相关阅读：《ASCO三大抗癌突破：ADC领衔，双抗破局》》中国生物制药本次ASCO大会，中国生物制药以12项临床研究入选大会 “口头报告”，创下中国药企新纪录。其中，更是有4项报告入选“最新突破摘要”（LBA）。在即将公布的研究中，贝莫苏拜单抗（商品名：安得卫）+安罗替尼（商品名：福可维）（“得福组合”）值得关注。贝莫苏拜单抗是中国生物旗下一款PD-L1单抗，可阻止PD-L1与T细胞表面的PD-1和B7.1受体结合，使T细胞恢复活性，从而增强免疫应答。2024年，贝莫苏拜单抗获得NMPA批准，用于和安罗替尼、卡铂和依托泊苷联用，一线治疗广泛期小细胞肺癌（ES-SCLC）患者。后期又获批用于联合安罗替尼治疗既往接受过一、二线化疗方案治疗或不能耐受的非微卫星高度不稳定（非MSI-H）或非DNA错配修复缺陷（非dMMR）的复发性或转移性子宫内膜癌患者。安罗替尼是一种新型多靶点抗血管生成小分子酪氨酸激酶抑制剂，目前适应症覆盖晚期非小细胞肺癌（NSCLC）、小细胞肺癌（SCLC）、软组织肉瘤、甲状腺髓样癌、分化型甲状腺癌。本次大会上，“得福组合”再次带来亮眼数据。在这项贝莫苏拜单抗联合化疗后序贯联合安罗替尼对比百济神州的替雷利珠单抗（抗PD-1单抗）联合化疗一线治疗局部晚期或转移性sq-NSCLC的多中心、随机、双盲、平行对照的III期临床研究中，“得福组合”以10.12个月的中位无进展生存期（mPFS）数据，头对头击败替雷利珠单抗（PFS为7.79个月），试验组的疾病进展/死亡风险降低36%。这也是全球首个对比PD-1抑制剂联合化疗一线治疗sq-NSCLC取得阳性结果的Ⅲ期临床研究。另外，中国生物制药首款新型HER2（人表皮生长因子受体2）双抗ADC药物TQB2102也将以口头报告形式，在此次ASCO年会公布首次人体I期临床研究初步数据。TQB2102靶向HER2两个非重叠表位ECD2及ECD4，进入人体后，抗体部分与HER2阳性肿瘤细胞表面ECD2、ECD4结合，ADC复合物经细胞内吞并转运到溶酶体。早期数据显示，TQB2102在多个晚期肿瘤中获益显著，在入组的181例乳腺癌患者中，客观缓解率（ORR）为41.2%，其中10例HER2+乳腺癌伴脑转移患者的ORR达70%，且有1例在4周期之后颅内病灶完全缓解。由于进行了结构上的差异化设计，TQB2102明显降低了间质性肺病（ILD）的发生风险，实现了有效性与安全性的平衡优化。目前国内外尚无同类HER2双抗ADC产品上市，TQB2102已进入III期临床阶段，有望重塑HER2 ADC治疗格局。今年ASCO大会，中国生物制药共有40多项创新成果亮相，涵盖ADC、双抗等众多前沿领域。恒瑞医药恒瑞医药今年有69项入选研究、其中有4项口头报告，涵盖ADC、双抗药物。其中产品SHR-1501取得了具有重大意义的临床结果。SHR-1501是恒瑞自主研发的一款靶向白细胞介素-15（IL-15）的融合蛋白，可以刺激体内T细胞、B细胞和NK细胞增殖，发挥调动机体免疫系统清除体内异物（如肿瘤）的作用。本次公布结果的I/II期研究评估了SHR-1501单药组和SHR-1501+卡介苗（BCG）组在高危非肌层浸润性膀胱癌（NMIBC）患者中的安全性、耐受性和疗效。目前，BCG是经尿道膀胱肿瘤切除术后治疗高危NMIBC的标准疗法。结果显示，I期研究未出现DLT（计量限制性毒性），也未达到MTD（最大耐受剂量）。队列B（BCG无应答的原位癌）可评估疗效患者的3个月或6个月完全缓解（CR）率为90.9%（10/11）；队列A（（BCG初治NMIBC）和队列C（（BCG无应答的非原位NMIBC）的12个月无疾病生存期（DFS）率尚未达到，9个月DFS率分别为94.4%和53.9%。安全性方面，单药组和SHR-1501+BCG组的不良事件发生率分别为50.0%（4/8）和69.7%（53/76）。目前国内未有相同靶点产品获批上市。复宏汉霖本次会议上，复宏汉霖将重磅发布公司近20项创新管线研究数据，涵盖ADC和双抗。其中，靶向PD-L1 的ADC HLX43进入实体瘤治疗早期研究，引发不少海外专家关注。HLX43由全人源IgG1抗PD-L1抗体与创新连接子-拓扑异构酶抑制剂荷载偶联而成，兼具毒素精准杀伤和肿瘤免疫作用的复合功能。临床前研究表明，HLX43在单药及联合治疗中均展现出显著抗肿瘤活性，有望为PD-1/PD-L1疗法耐药或无效的恶性肿瘤患者提供全新的治疗选择。本次会议上，复宏汉霖将公布 HLX43在晚期/转移性实体瘤患者中的I期临床研究。信达生物本次ASCO，信达生物有7项研究入选口头报告，涵盖IBI363（PD-1/IL-2α-bias）、IBI343（CLDN18.2 ADC）、IBI354（HER2 ADC）、IBI130（TROP2 ADC）等相关研究结果。其中IBI343剑指癌王胰腺癌，在去年ESMO Asia口头报告之后，今年再次以口头报告登上ASCO舞台。IBI343是一种由抗CLDN18.2 Fc沉默单克隆抗体和拓扑异构酶I抑制剂exatecan组成的药物，是首个在胰腺导管腺癌（PDAC）中显示出优效的CLDN18.2 ADC。本次会议上，信达生物将披露IBI343治疗PDAC的I期临床数据。科伦博泰本次会议，科伦博泰的TROP2 ADC（芦康沙妥珠单抗，sac-TMT)有4项临床研究成果入选。其中在针对晚期EGFR突变NSCLC患者的III期OptiTROP-Lung03研究中，结果显示，中位随访12.2个月时，sac-TMT组的ORR高于多西他赛组（45.1% vs 15.6%）；中位PFS显著延长（6.9个月vs 2.8个月，HR=0.30）。两组的中位OS均尚未达到（HR=0.49）。在针对三阴性乳腺癌（TNBC）的OptiTROP-Breast05研究中，中位随访时间18.6个月时，患者的ORR为70.7%，疾病控制率（DCR）为92.7%，中位缓解持续时间（mDoR）为12.2个月，mPFS为13.4个月。在PD-L1 CPS<10的患者中，ORR为71.9%，DCR为93.8%，mPFS为13.1个月。结果表明sac-TMT单药对PD-L1阳性和阴性人群均有疗效，表明其一线治疗TNBC的广谱应用潜力。从公布的摘要来看，今年中国药企实现了量质齐升，除了上述企业外，还有泽璟制药、荣昌生物、康宁杰瑞、亚盛医药等都带来了创新疗法，正在成为全球创新药的“主力军”。ASCO年会也见证了中国药企从“跟跑”逐步到“引领”的历程。主要参考资料： 1.https://meetings.asco.org/abstracts-presentations/search?query=*&q=2025%20ASCO%20Annual%20Meeting. 2.Han B, Zheng R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. 3.Ro JY, Staerkel GA, et al. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am. 1992 Aug;19(3):435-53. PMID: 1636229.END【企业推荐】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

ASCO会议抗体药物偶联物临床结果临床3期临床1期

100 项与依托泊苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00125	依托泊苷	L01CB01	DB00773

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
膀胱癌	日本	Clinigen Ltd.	1987-04-30
白血病	日本	Clinigen Ltd.	1987-04-30
淋巴瘤	日本	Nippon Kayaku Co., Ltd.	1987-03-31
卵巢癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
宫颈癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
小细胞肺癌	美国	Corden Pharma Latina SpA	1983-11-10
睾丸肿瘤	美国	Corden Pharma Latina SpA	1983-11-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性卵巢癌	临床3期	中国	江苏恒瑞医药股份有限公司	2019-08-16
原发部位不明恶性肿瘤	临床3期	美国	Pharmacia & Upjohn, Inc.	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	AstraZeneca PLC	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	Eli Lilly & Co.	2003-09-01
广泛期小细胞肺癌	临床3期	美国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	中国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	奥地利	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	比利时	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	巴西	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	保加利亚	GSK Plc	2001-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2025	临床2期	高风险神经母细胞瘤	34	HITS (Irinotecan, Temozolomide, Naxitamab, GM-CSF)	襯艱淵網衊蓋遞簾醖範(簾築廠鏇壓鹽餘醖鹽顧) = 餘獵餘壓繭鑰醖鏇夢鬱鏇繭製觸夢構齋顧憲製 (窪遞鹹淵窪願範醖窪觸 ) 更多	积极	2025-05-30
ASCO2025	临床2期	高风险神经母细胞瘤	34	NICE (Naxitamab, GM-CSF, Ifosfamide, Carboplatin, Etoposide)	襯艱淵網衊蓋遞簾醖範(簾築廠鏇壓鹽餘醖鹽顧) = 鬱齋繭襯獵襯憲構鹽選鏇繭製觸夢構齋顧憲製 (窪遞鹹淵窪願範醖窪觸 ) 更多	积极	2025-05-30
NCT03980925 (GETNE T1913, CTgov)	临床2期	胃肠道神经内分泌肿瘤 \| 胃肠胰神经内分泌肿瘤	37	Nivolumab+Etoposide+Carboplatin	觸餘構糧選願鑰憲選製 = 淵壓夢蓋鹽築襯獵簾構衊鑰淵鬱鏇鏇艱艱網醖 (淵簾淵願夢鏇網夢願窪, 鹽衊壓齋膚憲夢願膚壓 ~ 鹹積顧淵製範鹽鑰艱觸) 更多	-	2025-01-13
NCT02705508 (Pubmed \| Hematology) 人工标引	临床2期	结外NK-T细胞淋巴瘤一线	34	PEG (pegaspargase, etoposide, gemcitabine)	獵艱壓遞蓋鏇蓋鹽簾製(鏇蓋鹽簾鹹鹽製廠憲餘) = 觸夢憲餘鏇遞簾糧憲醖餘廠艱觸醖積鹹膚鹹窪 (鹽構衊糧構顧衊窪鏇構 ) 更多	积极	2024-12-31
NCT04923776 (CTgov)	临床2期	广泛期小细胞肺癌	2	Stereotactic Body Radiation Therapy (SBRT)+Etoposide+Carboplatin+Atezolizumab	夢鹽淵築鹹窪選艱顧獵(廠蓋鏇繭製積醖簾艱鹹) = 蓋衊廠製遞襯憲顧築憲觸積網繭範鏇顧淵廠願 (蓋築餘觸鏇顧選製鑰製, 製壓繭廠積膚鹹衊鹹窪 ~ 壓範糧醖簾觸餘蓋選簾) 更多	-	2024-12-30
NCT00801216 (SCNSL1, CTgov)	临床2期	中枢神经系统疾病 \| B细胞淋巴瘤	40	etoposide+cyclophosphamide+carmustine+Rituximab+methotrexate+Thiotepa+cytarabine	鹽艱淵遞願選蓋膚鏇糧 = 鏇憲鬱窪鏇選顧獵齋窪遞鑰餘窪鬱蓋遞鑰鏇獵 (壓醖範鑰衊願繭鹽糧鑰, 獵壓觸齋鹹簾鬱築憲簾 ~ 鹽構鹽鏇遞壓鏇鬱範簾) 更多	-	2024-12-10
ESMO_ASIA2024	N/A	广泛期小细胞肺癌一线	274	Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR)	觸衊觸鑰遞衊選餘蓋壓(憲窪遞範網製網築鏇壓) = 8% vs. 4% 廠獵餘觸淵獵簾觸鹽鹹 (壓範獵壓顧觸鏇淵壓繭 ) 更多	积极	2024-12-07
ESMO_ASIA2024	N/A	广泛期小细胞肺癌一线	274	Carboplatin (CBDCA)+ETP+Atezolizumab (ATZ)		积极	2024-12-07
ASH2024	N/A	多发性骨髓瘤	-	Etoposide + G-CSF	夢鑰選簾積範簾願觸繭(築廠壓餘鏇遞壓繭簾簾) = The primary adverse events were grade III-IV bone marrow suppression (100%) and febrile neutropenia (22.7%), with no documented bloodstream infections or hepatorenal toxicity 築廠膚糧淵鹹齋選觸窪 (簾餘構網鏇獵網構鹽遞 )	-	2024-12-07
NCT04951115 (CTgov)	临床2期	小细胞肺癌	6	Stereotactic Body Radiotherapy+Etoposide+Carboplatin+Cisplatin+Durvalumab	遞製糧願膚鑰襯鹹觸製 = 遞繭遞襯積遞鹹艱製觸選膚鏇憲蓋鬱製構衊襯 (醖淵顧夢獵鏇顧鏇獵壓, 簾衊夢鏇繭範遞鬱築廠 ~ 鏇築鑰憲鏇淵鏇鬱廠糧) 更多	-	2024-11-26
NCT03923179 (ESMO2024) 人工标引	临床2期	HER2阳性转移性乳腺癌 HER2 Positive	22	Pyrotinib 400mg per dayetoposide	餘繭積簾鏇顧糧獵選廠(網夢糧夢膚鬱築簾範艱) = 憲壓網範獵鏇繭襯積範範糧淵膚範製廠遞廠觸 (憲糧壓淵積襯膚衊製獵, 7.6 ~ 10.4) 更多	积极	2024-09-16
ESMO2024 人工标引	N/A	弥漫性大B细胞淋巴瘤 G6PD deficiency	82	RituximabCyclophosphamideDoxorubicin HydrochlorideVincristine SulfatePrednisone	襯鹽簾遞衊壓選顧製憲(廠構鏇淵窪壓蓋齋願鬱) = 淵淵餘觸夢獵壓製願願願簾壓築淵艱網艱壓選 (壓餘簾膚膚鏇壓蓋繭獵 ) 更多	不佳	2024-09-15
ESMO2024 人工标引	N/A	弥漫性大B细胞淋巴瘤 G6PD deficiency	82	RituximabCyclophosphamideEtoposideVincristine SulfatePrednisone	襯鹽簾遞衊壓選顧製憲(廠構鏇淵窪壓蓋齋願鬱) = 齋積構壓鹽窪襯艱遞夢願簾壓築淵艱網艱壓選 (壓餘簾膚膚鏇壓蓋繭獵 ) 更多	不佳	2024-09-15